APLS Q3 2020 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$2B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$646,000

Gross Profit

$646,000100.0% margin

Operating Income

-$130M-20054.5% margin

Net Income

-$136M-21006.2% margin

EPS (Diluted)

$-1.79

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$104M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$768M

Total Liabilities

$662M

Stockholders' Equity

$106M

Cash & Equivalents

$416M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$646,000	$0	—
Gross Profit	$646,000	-$70M	+100.9%
Operating Income	-$130M	-$70M	-85.2%
Net Income	-$136M	-$70M	-94.3%